TrialCell reports. Medicine2026

Efficacy and biomarker exploration of anlotinib plus penpulimab in second-line ES-SCLC: Results from the phase 2 ALTER-L041 trial.

Liang Zeng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.